tiprankstipranks
Advertisement
Advertisement

DE:8F8 Stock Latest News

SynAct Pharma draws heightened partner interest as ADVANCE data boost resomelagon’s strategic appeal
Company AnnouncementsSynAct Pharma draws heightened partner interest as ADVANCE data boost resomelagon’s strategic appeal
7d ago
SynAct Pharma Leadership Locks Up Shares Through 2026 to Signal Long-Term Confidence
PremiumCompany Announcements
SynAct Pharma Leadership Locks Up Shares Through 2026 to Signal Long-Term Confidence
22d ago
SynAct’s RA Drug Resomelagon Delivers Positive Phase 2b Data, Fuels Partnering Push
PremiumCompany Announcements
SynAct’s RA Drug Resomelagon Delivers Positive Phase 2b Data, Fuels Partnering Push
22d ago
SynAct extends U.S. patent exclusivity for lead RA therapy resomelagon to 2044
PremiumCompany Announcements
SynAct extends U.S. patent exclusivity for lead RA therapy resomelagon to 2044
24d ago
SynAct Pharma’s AP1189 Trial Targets Viral Respiratory Risk: What Investors Should Watch
PremiumCompany Announcements
SynAct Pharma’s AP1189 Trial Targets Viral Respiratory Risk: What Investors Should Watch
25d ago
8F8
SynAct Pharma AGM Confirms No Dividend and Renews Mandate for New Share Issues
PremiumCompany AnnouncementsSynAct Pharma AGM Confirms No Dividend and Renews Mandate for New Share Issues
25d ago
SynAct Pharma Details Q1 2026 Progress in Inflammation-Focused Biotech Strategy
Premium
Company Announcements
SynAct Pharma Details Q1 2026 Progress in Inflammation-Focused Biotech Strategy
1M ago
SynAct Pharma Clarifies Large Shareholder’s Erroneous Share Sale Order
Premium
Company Announcements
SynAct Pharma Clarifies Large Shareholder’s Erroneous Share Sale Order
1M ago
SynAct Pharma to Showcase Lead Inflammation Drug Ahead of Key Rheumatoid Arthritis Data
PremiumCompany Announcements
SynAct Pharma to Showcase Lead Inflammation Drug Ahead of Key Rheumatoid Arthritis Data
2M ago
SynAct Pharma convenes AGM and opts to retain earnings
PremiumCompany Announcements
SynAct Pharma convenes AGM and opts to retain earnings
2M ago
SynAct Pharma Finishes Phase 2b Dosing in Rheumatoid Arthritis Study
PremiumCompany Announcements
SynAct Pharma Finishes Phase 2b Dosing in Rheumatoid Arthritis Study
2M ago
SynAct Pharma Targets New Partnerships Ahead of Key Resomelagon Data
PremiumCompany Announcements
SynAct Pharma Targets New Partnerships Ahead of Key Resomelagon Data
2M ago
SynAct Pharma Updates Nomination Committee Ahead of 2026 AGM
PremiumCompany AnnouncementsSynAct Pharma Updates Nomination Committee Ahead of 2026 AGM
2M ago
SynAct Pharma Publishes 2025 Annual Report on Inflammatory Disease Pipeline
Premium
Company Announcements
SynAct Pharma Publishes 2025 Annual Report on Inflammatory Disease Pipeline
3M ago
SynAct Pharma Raises Share Capital Through Directed Issue
Premium
Company Announcements
SynAct Pharma Raises Share Capital Through Directed Issue
3M ago
SynAct Pharma Starts Phase 2 Dengue Trial of Resomelagon in Brazil
PremiumCompany Announcements
SynAct Pharma Starts Phase 2 Dengue Trial of Resomelagon in Brazil
3M ago
SynAct Pharma Targets RA Partnerships With BIO-Europe Spring 2026 Showcase
PremiumCompany Announcements
SynAct Pharma Targets RA Partnerships With BIO-Europe Spring 2026 Showcase
4M ago
SynAct Pharma Sets Capital Markets Day as It Enters Key Clinical Inflection Point
PremiumCompany Announcements
SynAct Pharma Sets Capital Markets Day as It Enters Key Clinical Inflection Point
4M ago
SynAct Pharma Raises SEK 51.9 Million in Directed Share Issue to Strengthen Runway and Deal Leverage
PremiumCompany Announcements
SynAct Pharma Raises SEK 51.9 Million in Directed Share Issue to Strengthen Runway and Deal Leverage
4M ago
SynAct Pharma Plans SEK 45 Million Directed Share Issue to Bolster Clinical Runway
PremiumCompany AnnouncementsSynAct Pharma Plans SEK 45 Million Directed Share Issue to Bolster Clinical Runway
4M ago
SynAct Pharma Names New CFO Ahead of Pivotal Phase 2b Data
Premium
Company Announcements
SynAct Pharma Names New CFO Ahead of Pivotal Phase 2b Data
4M ago
SynAct Pharma Publishes 2025 Annual Results and Highlights R&D Focus
Premium
Company Announcements
SynAct Pharma Publishes 2025 Annual Results and Highlights R&D Focus
5M ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >